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Abstract Although imatinib is an effective treatment for chronic myelogenous 
leukemia (CML), and nearly all patients treated with imatinib attain some form of re­
mission, imatinib does not completely eliminate leukemia. Moreover, if the imatinib 
treatment is stopped, most patients eventually relapse (Cortes et al. in Clin. Can­
cer Res. 11:3425–3432, 2005). In Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 
2008), the authors presented a mathematical model for the dynamics of CML un­
der imatinib treatment that incorporates the anti-leukemia immune response. We use 
the mathematical model in Kim et al. (PLoS Comput. Biol. 4(6):e1000095, 2008) to  
study and numerically simulate strategic treatment interruptions as a potential ther­
apeutic strategy for CML patients. We present the results of numerous simulated 
treatment programs in which imatinib treatment is temporarily stopped to stimulate 
and leverage the anti-leukemia immune response to combat CML. The simulations 
presented in this paper imply that treatment programs that involve strategic treatment 
interruptions may prevent leukemia from relapsing and may prevent remission for 
signiﬁcantly longer than continuous imatinib treatment. Moreover, in many cases, 
strategic treatment interruptions may completely eliminate leukemic cells from the 
body. Thus, strategic treatment interruptions may be a feasible clinical approach to 
enhancing the effects of imatinib treatment for CML. We study the effects of both 
the timing and the duration of the treatment interruption on the results of the treat­
ment. We also present a sensitivity analysis of the results to the parameters in the 
mathematical model. 
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1 Introduction 
Chronic myelogenous leukemia (CML) results from the uncontrolled growth of white 
blood cells due to increased and unregulated growth of predominantly myeloid cells 
in the bone marrow and the accumulation of these cells in the blood (Sawyers 2000). 
The standard treatment for CML is the tyrosine kinase inhibitor imatinib mesylate 
(marketed as Gleevec or Glivec) (Angstreich et al. 2004). Although imatinib is an 
effective treatment for CML and most patients attain some form of remission, ima­
tinib does not completely eliminate all leukemia cells, and if the imatinib treatment 
is stopped, most patients eventually relapse (Cortes et al. 2005; Michor et al. 2005) 
(though we do note that in some recent clinical ﬁndings, e.g., (Rousselot et al. 2007; 
Mahon et al. 2009), several patients have demonstrated relapse-free survival after 
imatinib discontinuation). There are three standard types of remission: hematologic, 
cytogenetic, and molecular. Each layer corresponds to a 2-log, or 100-fold, difference 
from the previous layer. According to (Lowenberg 2003), each patient typically has 
approximately 1012 leukemia cells prior to imatinib treatment. Hence, hematologic 
remission corresponds to 1010 cells, cytogenetic remission corresponds to 108 cells, 
and molecular remission corresponds to 106 cells. Assuming that the average person 
has approximately 6 liters of blood, these remission levels correspond to the concen­
tration levels given in Table 1. With imatinib treatment, nearly all patients achieve 
hematologic remission (Lee 2000), and approximately 75% of patients achieve cyto­
genetic remission (Cortes et al. 2005). 
Several recent mathematical models have been developed to study the dynam­
ics of CML under imatinib treatment, including (Komarova and Wodarz 2005; 
Michor et al. 2005; Kim et al. 2008), and (Roeder et al. 2006). In all of these studies, 
the authors conclude that imatinib does not completely eliminate the leukemia cell 
population, and propose that imatinib therapy should be combined with an additional 
form of treatment. In (Michor et al. 2005), the authors develop a four-compartment 
differential equations model based on the known biology of the hematopoietic sys­
tem to model the dynamics of CML with imatinib treatment. In (Kim et al. 2008), the 
authors incorporate the anti-leukemia immune response in CML patients on imatinib 
Table 1 Leukemia cell concentrations (in k/µL) corresponding to hematologic, cytogenetic, and molecu­
lar remission levels 
Remission level Hematologic Cytogenetic Molecular 
Concentration (k/µL) 1.67 1.67 × 10−2 1.67 × 10−4 
therapy to the model proposed in (Michor et al. 2005) by adding interactions with 
anti-leukemia T-cells. The authors of (Kim et al. 2008) formulate their mathematical 
model as a system of delay-differential equations (DDEs), and demonstrate that the 
immune response may play a critical role in determining the length of time that CML 
patients on imatinib treatment remain in remission. 
In this paper, we present a strategic treatment interruption treatment strategy for 
CML based on the delay differential equation model proposed in (Kim et al. 2008). 
We use the model in (Kim et al. 2008) to numerically determine an optimal time 
period during which imatinib treatment should be temporarily stopped in order to 
leverage the anti-leukemia immune response. Although the leukemia load initially 
suppresses the T-cell immune response, a small number of T-cells remain and can 
eventually be leveraged to potentially eradicate leukemia. We demonstrate that such 
a strategic treatment interruption signiﬁcantly improves the efﬁcacy of imatinib treat­
ment for CML patients. In particular, the results of our simulations suggest that, in 
many cases, leukemia can be completely eliminated with a strategic treatment inter­
ruption timed during the patient’s own anti-leukemia immune response. In (Kim et 
al. 2008), the authors consider total leukemia elimination to be complete if the total 
cancer population in the body is below 1 cell, i.e., 
Total cancer concentration < 10−10 k/µL, 
assuming that the average patient has about 6 L of blood. Since the mathematical 
model presented in (Kim et al. 2008) is a continuous deterministic system, in reality, 
the model never allows the total cancer population to actually reach 0. Since a total 
cancer concentration of 10−10k/µL corresponds to less than one cancer cell in the 
blood, this is a reasonable indicator for total cancer elimination. 
This paper is organized in the following way. In Sect. 2, we provide an overview 
of the delay-differential equation model for the dynamics of CML, imatinib, and the 
anti-leukemia immune response presented in (Kim et al. 2008). In Sect. 3, we propose 
several strategic treatment interruption treatment programs for CML patients based 
on the anti-leukemia immune response described in (Kim et al. 2008), and we present 
and analyze the results of these simulated treatment plans. In particular, we study 
the effects of changing the timing and duration of the treatment interruption on the 
time required for the patient to achieve cytogenetic remission and (in many cases) 
the time required for total cancer elimination. In Sect. 4, we study the sensitivity of 
the results to the universal and patient-speciﬁc parameters used in the mathematical 
model. We discuss conclusions, drawbacks of the mathematical model used for our 
numerical analysis, and areas for further research in Sect. 5. In Appendix A, we derive 
an explicit, closed-form solution for the mathematical model for CML presented in 
(Michor et al. 2005). 
2 A Mathematical Model for CML with Imatinib Treatment 
Michor et al. (2005), used data from 169 patients to develop and analyze a mathemat­
ical model for CML. In this model, leukemia cells are assumed to develop through 
four stages of differentiation. The different cell populations at time t are denoted as 
follows: y0(t), leukemia stem cells; y1(t), progenitor cells; y2(t), differentiated cells; 
and y3(t), terminally differentiated cells. Leukemia cells progress through the vari­
ous stages in the following way. Stem cells regenerate themselves at rate ry . Stem  
cells expand and progress to become progenitor cells at rate ay and die at rate r0. 
Progenitor cells become differentiated cells at rate by and die at rate d1. Differen­
tiated cells expand and progress to become terminal cells at rate cy and die at rate 
d2. Terminal cells die at rate d3. With imatinib treatment, the rate at which leukemia 
cells pass from one stage to the next is greatly reduced, thus causing a rapid drop 
in the leukemia population. In particular, according to this model, imatinib treatment 
reduces the parameters ay and by by 100-fold and 750-fold, respectively. For the ini­
tial conditions, it is assumed that all four leukemia compartments are in steady state 
relative to one another. 
In addition, Michor et al. included a second set of leukemia cells to incorporate 
the possibility of imatinib-resistant mutations. It was assumed that the only cells that 
can acquire imatinib-resistant mutations are stem cells, and they mutate at a rate u 
per division. In this paper, we will assume that there are no imatinib-resistant muta­
tions (i.e., u = 0), so we do not include the second set of differential equations here. 
However, we describe them in Appendix A. The system of ODEs that describes the 
model for the leukemia cell populations is given below. Although Michor et al. did 
not derive an explicit solution for this system of differential equations in their origi­
nal work, the system can be solved exactly using diagonalization and we present the 
solution in Appendix A: 
dy0 � � = ry(1 − u) − d0 y0, 
dt 
dy1 = ayy0 − d1y1, 
dt 
dy2 = byy1 − d2y2, 
dt 
dy3 = cyy2 − d3y3. 
dt 
In (Kim et al. 2008), the authors modiﬁed this model to incorporate an anti-
leukemia immune T-cell response into the ODE model. The motivation for their 
model is based on experimental data taken from (Chen et al. 2008), in which the 
authors conducted TNF-α and IFN-γ ELISPOT analyses at multiple time points to 
measure the evolution of the anti-leukemia T-cell responses of CML patients under­
going imatinib treatment. To incorporate the dynamics of the imatinib-induced T-cell 
immune response in the system of equations governing the CML dynamics, the au­
thors of (Kim et al. 2008) added interactions with T-cells and a delay-differential 
equation to model the T-cell population. In the modiﬁed system, each equation con­
tains an added term which accounts for the death of leukemia cells as a result of an 
interaction with T-cells. In addition, a delay-differential equation is included for the 
population T of anti-leukemia T-cells. The leukemia cell death rates di,0 ≤ i ≤ 3, 
in (Michor et al. 2005) correspond to the natural death rates of the leukemia popula­
tions under imatinib treatment. In the DDE model of (Kim et al. 2008), the authors 
distinguish between the natural death rate of leukemia and the death rate due to the 
cytotoxic T-cell response. Thus, the death rates di in the DDE model are a fraction, λ, 
of the combined death rates estimated in (Michor et al. 2005). The parameter λ rep­
resents the fraction of the leukemia cell deaths that results from nonimmune (versus 
immune) causes. It is assumed that λ is greater than 0.5, so that the anti-leukemia im­
mune response contributes to less than half of the decline in leukemia under imatinib 
treatment (Kim et al. 2008). In (Kim et al. 2008), the authors set λ = 0.75; we include 
a discussion of the sensitivity of our results on the choice of λ. Following (Kim et al. 
2008), we assume that u = 0 and that there are no imatinib-resistant leukemia cells. In 
Sect. 5, we discuss the possibility of acquired imatinib resistance. The mathematical 




= (ry − d0)y0 − qCp(C,T )y0, 
dy1 
dt 
= ayy0 − d1y1 − qCp(C,T )y1, 
dy2 
dt 
= byy1 − d2y2 − qCp(C,T )y2, 
dy3 
dt 
= cyy2 − d3y3 − qCp(C,T )y3, 
dT 
dt 
= sT − dT T − p(C,T )C + 2np(Cnτ , Tnτ )qT Cnτ , 




Cnτ = C(t − nτ), Tnτ = T (t  − nτ). 
(1) 
(2) 
The variables in this model are the same as those in the model of Michor et al. 
(2005), with the exception of the new variables C and T . The variable C represents 
the total concentration of all leukemia cells. The variable T represents the concen­
tration of anti-leukemia T cells. The ﬁnal terms qCp0e −cnCkT yi follow the law of 
mass action. The kTyi is the rate of interaction between anti-leukemia T-cells and 
the leukemia cell subpopulation yi , where k is the mixing coefﬁcient. The coefﬁ­
cient p0 is the probability that a T-cell engages the cancer cell upon interaction, and 
qC is the probability that the cancer cell dies from the T-cell response. Moreover, 
leukemia cells suppress the anti-leukemia T-cell immune response, and although the 
precise mechanism is unknown, this model assumes that the level of down-regulation 
depends on the current cancer population. The probability that a T-cell engages a can­
cer cell is modeled as an exponential decay as a function of the cancer concentration. 
−cnCThus, the probability of a productive T-cell interaction with a cancer cell is p0e , 
where cn is the rate of exponential decay due to negative pressure. We note that the 
authors of Kim et al. (2008) model T-cell dynamics in particular because T-cells are 
the main mediators of the anti-leukemia response, as has been demonstrated by the 
major role that cytotoxic T-cells play in curing leukemia after an allogenic stem cell 
transplant. By extension, they are hypothesizing that autologous T-cells will also be 
the key players in the anti-leukemia immune response. 
In the delay-differential equation (2) for modeling the anti-leukemia T-cell re­
sponse, the parameter sT denotes the constant supply rate of T-cells into the system 
from stem cells. The parameter dT represents the natural death rate of T-cells, and 
p(C,T )C is the rate at which T-cells engage leukemia cells and commit to n rounds 
of division. The ﬁnal term represents the population increase due to n divisions of 
stimulated T-cells, where τ is the average duration of one division, and Cnτ and Tnτ 
are the time delayed cancer and T-cell concentrations, respectively. The coefﬁcient qT 
is the probability that a T-cell survives the encounter with an activated leukemia cell. 
Once a T-cell is stimulated, it exits the collection of interacting T-cells and re-enters 
the system nτ time units later after n divisions. 
The estimated universal and patient-dependent parameter values for this system 
are given in Table 2 (and are taken from (Michor et al. 2005) and (Kim et al. 2008)). 
The parameters n, sT , dT , and cn are patient-dependent parameters, and in (Kim et 
al. 2008) the authors use experimental data for CML patients on imatinib treatment 
published by Chen et al. (2008) to estimate values for these parameters for particular 
patients. It is our goal here to demonstrate numerically that strategically timed treat­
ment interruptions may lead to total eradication of cancerous cells, and we wish to 
study here the activation of T-cells as a general feature, rather than to focus on partic­
ular patient-dependent data sets. Thus, we will present detailed numerical results here 
for simulations using the parameter values in Table 2, which are representative of the 
parameter values for all patient data in (Chen et al. 2008). To study the impact of the 
particular numerical values of the parameters on our results, we present an extensive 
sensitivity analysis in Sect. 4, and we vary the parameters to include the ranges of the 
parameter values for all patients analyzed in (Chen et al. 2008). 
In Fig. 1, we illustrate the results of simulating the delay-differential equations 
model presented in (Kim et al. 2008) without imatinib treatment, i.e., ay = 1.6 and 
by = 10. We plot the total leukemia cell concentrations �i3 =0 yi for 0 ≤ t ≤ 500 days. 
We observe that without imatinib treatment, the cancer population grows rapidly. 
Moreover, we note that without treatment, the immune response is fully suppressed 
and the T-cell concentration remains at the initial steady state sT /dT . 
Next, in Fig. 2, we illustrate the results of simulating the delay-differential equa­
tions model of Kim et al. (2008) with continuous imatinib treatment, i.e., ay = 1.6/10 





=0 yi and the T-cell concentrations T (t)  for 0 ≤ t ≤ 1200 days. In (Kim 
et al. 2008), it has been demonstrated that this model that includes the anti-leukemia 
T-cell response provides a closer ﬁt to the immunological data than the Michor model 
(Michor et al. 2005) that does not include the immune response. In particular, we note 
that the 2005 model of Michor et al. (2005) predicts that leukemia relapses after 15 
to 24 months, despite continued imatinib treatment. However, this contradicts clini­
cal observations in imatinib-treated patients, who generally remain in remission well 
beyond 30–40 months, as described in Piazza et al. (2006). With the addition of the 
  
Table 2 Estimates of parameters (Kim et al. 2008; Michor et al. 2005) 
Parameter Description Estimate 
λ Fractional adjustment constant 0.75 
d0 Stem cell death rate 0.003 λ/day 
d1 Progenitor cell death rate 0.008 λ 
d2 Differentiated cell death rate 0.05 λ 
d3 Terminal cell death rate λ 
ry Stem cell regeneration rate 0.008/day 
ay Stem cell growth rate 1.6 (without imatinib treatment) 
1.6/100 (with imatinib treatment) 
by Progenitor cell growth rate 10 (without imatinib treatment) 
10/750 (with imatinib treatment) 
cy Differentiated cell growth rate 100 
rz Imatinib resistant mutation 
stem cell regeneration rate 0.023/day 
az Imatinib resistant 
mutation stem cell growth rate 1.6 
bz Imatinib resistant mutation 
progenitor cell growth rate 10 
cz Imatinib resistant mutation 
differentiated cell growth rate 100 
k Kinetic (mixing) coefﬁcient 1 (k/µL)−1/day 
p0 Probability that T-cell engages cancer cell 0.8 
qC Probability that cancer cell dies from 
encounter with T-cell 0.75 
qT Probability that T-cell survives 
encounter with cancer cell 0.5 
τ Duration of one T-cell division 1 day 
n Average number of T-cell divisions 1.2 
dT Anti-leukemia T-cell death rate 0.001/day 
sT Anti-leukemia T-cell supply rate 1.2 × 10−6 (k/µL)/day 
cn Decay rate of immune responsivity 1 (k/µL)−1 
y0(0) Initial leukemia stem cell concentration 1.8 × 10−5k/µL 
T-cell response in the model of Kim et al. (2008), persistence of anti-leukemia T-cells 
even at low levels prevents leukemia from relapsing for up to 50 months. 
The graphs in Fig. 2 illustrate several important points about the dynamics of CML 
under imatinib treatment and the imatinib-induced immune response as described by 
the DDE model of Kim et al. (2008). As soon as imatinib treatment begins, there 
is a sharp decline in the leukemia cell concentrations. Although imatinib drives the 
cancer population to low levels, it does not completely eliminate the leukemia stem 
cells, and the result is a situation in which leukemia is never completely eliminated. 
In particular, we note that the minimum total cancer concentration predicted by the 
  
Fig. 1 Total leukemia 
concentration without imatinib 
treatment for 0 ≤ t ≤ 500 days 
Fig. 2 The logarithm of the 
leukemia concentration and the 
T-cell concentration with 
continuous imatinib treatment 
model before cytogenetic relapse is 1.1 × 10−4 k/µL. Assuming that an average per­
son has approximately 6 liters of blood, this concentration level corresponds to a total 
leukemia cell population of half a million to a million cells. We also observe that the 
model predicts that with continuous imatinib treatment, the patient will eventually 
relapse. These observations demonstrate an important point, namely that the model 
does not predict that CML is eliminated by imatinib treatment alone. However, the 
model does predict that it takes signiﬁcantly more time for the disease to relapse 
when compared with the Michor model that does not include the immune response. 
In addition, we observe ﬂuctuations in the anti-leukemia T-cell concentrations that 
correspond to changes in the leukemia cell concentrations. Initially, the T-cell con­
centrations remain low, close to the steady-state level, as the immune response is fully 
suppressed by leukemia. As the leukemia cell concentrations decrease, the patient’s 
immune response is eventually stimulated and the T-cell concentrations increase ac­
  
cordingly. When the leukemia cell populations become sufﬁciently low, the T-cells 
are no longer stimulated and begin to contract. As a result, the immune response does 
not expand sufﬁciently to eliminate the leukemia cells. It is clear from these obser­
vations that there is a critical time period during which the anti-leukemia immune 
response is activated. If the leukemia cell concentration is too high, the immune re­
sponse is fully suppressed. On the other hand, if the leukemia cell concentration is 
too low, the immune response will not be sufﬁciently stimulated. For reference, we 
note that the T-cell population begins increasing at t = 90 days, and the maximum 
T-cell concentration is 3.09 × 10−2k/µL at t = 206 days. 
3 Strategic Treatment Interruptions 
Strategic treatment interruptions (STIs), also known as “structured treatment inter­
ruptions” or “supervised treatment interruptions” are planned interruptions of drug 
treatment designed to reduce and/or relieve the side effects of the drugs, to reduce 
drug resistance, and/or to stimulate the immune response. In this section, we study 
several treatment interruption plans for imatinib treatment of CML based on the math­
ematical model for CML discussed in Sect. 2. In particular, we attempt to improve 
the effectiveness of treatment by strategically interrupting imatinib treatment in order 
to leverage the patient’s own anti-leukemia immune response. 
Strategic treatment interruptions have been studied extensively for patients 
with chronic HIV infection being treated with highly active antiretroviral therapy 
(HAART) (Adams et al. 2004; Bajaria et al. 2004; Koup 2004; Maserati et al. 2007). 
In this context, strategic treatment interruptions were motivated primarily by the de­
velopment of drug resistance, evolution of viral strains, detrimental short- and long-
term side effects, and patient complications (Bajaria et al. 2004). Numerous studies 
have been conducted to explore the beneﬁts of strategic treatment interruptions for 
HIV treatment, but the results vary widely and are highly dependent on treatment 
schedules, starting times, and patient-speciﬁc factors. 
In this work, however, we are primarily interested in the use of strategic treatment 
interruptions as a technique for leveraging the patient’s own anti-leukemia immune 
response to combat CML. In this ﬁrst study, we perform several simulations in which 
we temporarily stop imatinib treatment once. We vary the length of the interruption 
and the starting time of the interruption, and measure the time required for the patient 
to achieve cytogenetic remission and the time required for total cancer elimination 
(if total elimination occurs). We assume that when imatinib is stopped, the stem cell 
and progenitor cell growth rates (ay and by , respectively) immediately return to their 
values without imatinib treatment (1.6 and 10, respectively). Similarly, we assume 
that when imatinib is restarted, ay returns to 1.6/100 and by returns to 10/750 imme­
diately. 
In Tables 3 and 4, we present the results of several 15-day and 30-day strate­
gic treatment interruption simulations. In each of these studies, we simulate a single 
treatment interruption in an attempt to leverage the ﬁrst immune response increase. 
Imatinib treatment is temporarily stopped on a speciﬁed day for either 15 or 30 days. 
In Fig. 3, we plot the base-10 logarithm of the total leukemia cell concentration and 
  
Table 3 Results of several 15-day strategic treatment interruption (abbreviated as STI above) plans. For 
each simulation, we report the ﬁrst day of the 15-day treatment interruption, the maximum leukemia con­
centration that occurs after the interruption, the time required for the patient to achieve cytogenetic remis­
sion, and the time required for total cancer elimination (i.e., concentration < 10−10k/µL) 
Treatment Maximum leukemia Time until Time until 
plan: First concentration cytogenetic total cancer 
day of (k/µL) after remission elimination 
15-day STI interruption (days) (days) 
No STI n/a 251 n/a 
90 20.6 at t = 106 312 n/a 
120 17.25 at t = 136 313 n/a 
150 14.58 at t = 166 316 879 
180 11.71 at t = 196 329 665 
210 8.96 at t = 226 346 616 
240 6.75 at t = 256 365 606 
270 5.14 at t = 286 386 611 
300 4.01 at t = 316 408 627 
330 3.21 at t = 346 433 655 
360 2.64 at t = 376 459 693 
390 2.23 at t = 406 487 739 
Table 4 Results of several 30-day strategic treatment interruption (abbreviated as STI above) plans. 
For each simulation, we report the ﬁrst day of the 30-day strategic treatment interruption, the maximum 
leukemia concentration that occurs after the interruption, the time required for the patient to achieve cyto­
genetic remission, and the time required for total cancer elimination (i.e., concentration < 10−10k/µL) 
Treatment Maximum leukemia Time until Time until 
plan: First concentration cytogenetic total cancer 
day of (k/µL) after remission elimination 
30-day STI interruption (days) (days) 
No STI n/a 251 n/a 
90 34.6 at t = 121 342 n/a 
120 31.35 at t = 151 345 n/a 
150 28.30 at t = 181 350 929 
180 24.33 at t = 211 364 711 
210 19.92 at t = 241 382 662 
240 16.07 at t = 271 404 654 
270 13.06 at t = 301 426 656 
300 10.77 at t = 331 449 666 
330 9.05 at t = 361 473 681 
360 7.75 at t = 391 498 699 
390 6.75 at t = 421 524 722 
the T-cell concentrations for 0 ≤ t ≤ 1200 days with continuous imatinib treatment 
(upper left), with a 15-day strategic treatment interruption from t = 300 days until 
t = 315 days (upper right), and with a 30-day strategic treatment interruption from 
  
Fig. 3 Logarithm of the leukemia concentrations and the T-cell concentrations for 0 ≤ t ≤ 1200 days 
with continuous imatinib treatment (upper left), with a 15-day treatment interruption (STI) from t = 300 
to t = 315 days (upper right), and with a 30-day treatment interruption from t = 180 to t = 210 (lower). 
The treatment interruption is indicated with vertical lines 
t = 180 days until t = 210 days (lower). In each graph, the timing of the treatment 
interruption is marked with vertical lines. These graphs demonstrate the general dy­
namics of the leukemia and T-cell concentrations for all the simulations described 
in Tables 3 and 4, so we include only these illustrative cases here. For ease of com­
parison amongst the scenarios, the axis scales (minimum and maximum values) are 
the same for each of the three treatment strategies presented in Fig. 3. With the start 
of imatinib treatment at time t = 0, the leukemia cell concentration begins decreas­
ing rapidly, and at approximately 90 days, the leukemia cell concentration is small 
enough that the immune response is no longer signiﬁcant and the T-cell concentra­
tion begins increasing. As a result of the strategic treatment interruption, there is a 
small, fast rise in the concentration of leukemia cells while the imatinib treatment 
is stopped. However, this increase does not reach the initial level of leukemia cells 
present in the patient. Eventually, after imatinib treatment is restarted, the leukemia 
cell concentration falls below the level of cytogenetic remission. For the second case 
(treatment interruption for 300 ≤ t ≤ 315 days) illustrated in Fig. 3, the leukemia 
concentration ﬁrst falls below the level of cytogenetic remission 408 days after the 
start of treatment, and after 627 days, cancer has been completely eliminated. 
In each table, we present the ﬁrst day of the treatment interruption, the maxi­
mum leukemia cell concentration that occurs after the treatment interruption occurs, 
  
Fig. 4 Summary of the results of several 15-day and 30-day strategic treatment interruptions. Upper left: 
The maximum leukemia concentration (k/µL) that occurs after the interruption vs. starting day of the 
treatment interruption. Upper right: Time (in days) until cytogenetic remission vs. starting day of the 
treatment interruption. Lower: Time (in days) until complete leukemia elimination vs. starting day of the 
treatment interruption 
the time required for the patient to achieve cytogenetic remission, and the time re­
quired for total cancer elimination (i.e., total concentration <10−10k/µL). In almost 
all cases, the strategic treatment interruption strategies that we consider result in total 
cancer elimination within the ﬁrst 3 years of treatment. For reference, we note that 
the minimum total cancer concentration predicted by the mathematical model with a 
15-day treatment interruption beginning at t = 300 is 1.52 × 10−26k/µL, which cor­
responds to a total cancer cell count of 9.12 × 10−17 cells (assuming 6 L of blood). 
This minimum concentration is signiﬁcantly lower than (several orders of magnitude) 
the cancer elimination criterion of 10−10k/µL. 
We summarize the results presented in Tables 3 and 4 with a series of graphs. In 
Fig. 4, we plot the maximum leukemia concentration (k/µL) that occurs after the 
interruption vs. starting day of the treatment interruption (upper left); the time (in 
days) until cytogenetic remission vs. starting day of the treatment interruption (upper 
right); and the time (in days) until complete leukemia elimination vs. starting day of 
the treatment interruption (lower). 
  
In Sect. 4, we perform several hundred simulations in which we vary the para­
meters in Tables 2 over a wide range that includes the biologically relevant values 
determined by the data presented in (Chen et al. 2008). 
The results presented in Tables 3 and 4 demonstrate that there is a tradeoff between 
the starting time of the treatment interruption, the maximum cancer concentration ob­
served after the interruption, and the time required for the patient to achieve cytoge­
netic remission and total cancer elimination. As the starting time of the interruption 
increases, the maximum cancer concentration observed due to the spike after imatinib 
is stopped decreases, and the time required until cytogenetic remission and total can­
cer elimination increases. Thus, before clinical implementation of strategic treatment 
interruptions for CML patients, these issues should be studied in more detail, and the 
individual treatment goals of each patient should be taken into consideration when 
devising a treatment plan. 
4 Sensitivity Analysis 
In this section, we conduct a sensitivity analysis of the model parameters with respect 
to the effectiveness of the strategic treatment interruption strategies. We apply the 
Latin Hypercube sampling (LHS) method described in (McKay et al. 1979). The LHS 
technique provides a method for simultaneously sampling a wide range of parameters 
and statistically determining the correlation between the values of the parameters and 
various outcomes. We simulate the delay-differential equation model with various 
strategic treatment interruptions several thousand times with randomly sampled sets 
of parameters; using LHS, the values of the parameters are chosen in such a way that 
each parameter is well distributed over its range of possible values. In particular, the 
parameters are sampled uniformly over the ranges given in Table 5. We vary every  
parameter and initial condition used in the model. 
We provide in Table 5 the Pearson product-moment correlation (PPMC) and 
Spearman rank-order correlation (SROC) coefﬁcients between each parameter and 
the minimum cancer concentration attained during the course of treatment before the 
model predicts a relapse above the level of cytogenetic remission. To obtain the cor­
relation coefﬁcients in Table 5, we performed 1000 LHS simulations with a strategic 
treatment interruption from t = 300 to t = 315 days after the start of treatment, but 
we note that the correlation coefﬁcients obtained with all other strategic treatment 
interruption strategies considered in Sect. 3 are comparable. We also note that the 
relationship between the parameter values and the minimum cancer concentration is 
monotonic. 
As indicated in Table 5, the most sensitive parameters are n (the average number 
of T-cell divisions per stimulation), qT (the probability that a T-cell survives an en­
counter with a leukemia cell), and cn (the rate of exponential decay in the probability 
of a productive T-cell interaction with a cancer cell, or the level of immune down-
regulation). Since we are speciﬁcally timing the interruption to leverage the patient’s 
own immune response, it makes sense that the parameters that are most sensitive to 
the effectiveness of treatment are those that are directly related to T-cell activity. We 
note that as a potential clinical application for treatment of CML, these parameters 
  
Table 5 Sensitivity analysis of the parameters used in the DDE model for a 15-day strategic treatment 
interruption from t = 300 to t = 315. For each parameter, we report the estimate of the parameter, the range 
used for Latin Hypercube sampling, and the Pearson product-moment correlation (PPMC) and Spearman 
rank-order correlation (SROC) coefﬁcients between the parameter and the minimum cancer concentration. 
To obtain the correlation coefﬁcients, we performed 1000 simulations in which every parameter was varied 
over the given range 
Parameter Estimate Range PPMC SROC 
λ 0.75 0.5 to 1 −0.1438 −0.0866 
d0 0.003 λ/day ±25% −0.0217 0.0158 
d1 0.008 λ ±25% −0.0135 0.0625 
d2 0.05 λ ±25% −0.1238 0.0566 
d3 λ ±25% 0.0364 0.0718 
ry 0.008/day ±25% 0.0342 0.0195 
ay 1.6 without imatinib ±25% 0.0224 −0.0235 
1.6/100 with imatinib 
by 10 without imatinib ±25% 0.0218 0.0077 
10/750 with imatinib 
cy 100 ±25% 0.0668 −0.0708 
rz 0.023 /day ±25% −0.0319 −0.0323 
az 1.6 Same as ay 0.0224 −0.0235 
bz 10 Same as by 0.0218 0.0077 
cz 100 Same as cy 0.0668 −0.0708 
u 0/division 4 × 10−8 − 8 × 10−8 −0.0854 −0.0889 
k 1 (k/µL)−1/day ±25% −0.0871 −0.1246 
p0 0.8 ±25% −0.0981 −0.1298 
qC 0.75 ±25% −0.0307 −0.0526 
qT 0.5 ±25% −0.1174 −0.2229 
τ 1 day 12–24 hours 0.0732 0.1217 
n 1.17 to 2.2 1 to 3 −0.2534 −0.4543 
dT 1 − 7 × 10−3d/ay 1 × 10−3 to 1 × 10−2 0.1444 0.0372 
sT 1 × 10−5 to 1 × 10−6 k/µL/day 1 × 10−5 to 1 × 10−6 −0.0499 −0.0852 
cn 0.8 to 7/day 0 to 10 0.1637 0.3921 
C(0) 23.1–116.8 k/µL 20 to 200 0.0947 0.0414 
should be measured before and during treatment so that the strategic treatment in­
terruption plan can be constructed to optimize the anti-leukemia immune response. 
In addition, in Table 6 we present the results of several thousand strategic treatment 
interruption simulations using the parameter ranges described in Table 5. In partic­
ular, for each strategic treatment interruption, we perform 500 simulations in which 
every parameter is randomly varied over the ranges given in Table 5. In Table 6, we  
report the fraction of these simulations that result in a successful treatment. Here, a 
successful treatment is a simulation in which the total cancer population falls below 
the total elimination criterion. 
  
Table 6 Results of LHS sensitivity analysis of the parameters in Table 5. For each strategic treatment 
interruption (abbreviated as STI above) plan, 500 simulations are performed in which every parameter is 
randomly varied over the ranges given in Table 5. We report the fraction of LHS samples that result in a 
successful treatment. A success is deﬁned as a simulation in which the total cancer population falls below 
10−10k/µL 
Treatment Fraction of Treatment plan: Fraction of 
plan: successful plan: successful 
STI days treatments STI days treatments 
90 ≤ t ≤ 105 0.488 120 ≤ t ≤ 135 0.544 
150 ≤ t ≤ 165 0.568 180 ≤ t ≤ 195 0.450 
210 ≤ t ≤ 225 0.544 240 ≤ t ≤ 255 0.546 
270 ≤ t ≤ 285 0.468 300 ≤ t ≤ 315 0.650 
330 ≤ t ≤ 345 0.512 360 ≤ t ≤ 375 0.486 
390 ≤ t ≤ 405 0.474 90 ≤ t ≤ 120 0.434 
120 ≤ t ≤ 150 0.458 150 ≤ t ≤ 180 0.480 
180 ≤ t ≤ 210 0.516 210 ≤ t ≤ 240 0.542 
240 ≤ t ≤ 270 0.566 270 ≤ t ≤ 300 0.588 
300 ≤ t ≤ 330 0.624 330 ≤ t ≤ 360 0.578 
360 ≤ t ≤ 390 0.550 390 ≤ t ≤ 420 0.542 
90 ≤ t ≤ 135 0.450 150 ≤ t ≤ 195 0.524 
210 ≤ t ≤ 255 0.578 270 ≤ t ≤ 315 0.624 
330 ≤ t ≤ 375 0.528 390 ≤ t ≤ 435 0.536 
450 ≤ t ≤ 495 0.530 510 ≤ t ≤ 555 0.544 
570 ≤ t ≤ 615 0.528 630 ≤ t ≤ 675 0.526 
690 ≤ t ≤ 735 0.518 750 ≤ t ≤ 795 0.494 
5 Discussion and Concluding Remarks 
In this paper, we have presented the results of numerous strategic treatment inter­
ruption simulations for CML patients being treated with imatinib. This study used 
the mathematical model presented in (Kim et al. 2008), which models the dynamics 
between CML, imatinib, and the patient’s own immune response, to simulate strate­
gic treatment interruption programs designed to leverage the anti-leukemia immune 
response. Mathematical modeling is an important tool for investigating the dynam­
ics of this complex system, and it provides the ability to simulate and investigate 
treatment interruption therapy techniques as a possible treatment for CML patients. 
We have demonstrated numerically that strategically-timed imatinib treatment inter­
ruptions could lead to a potential cure for CML, and that the effectiveness of the 
treatment depends on the starting time of the treatment interruption and the length of 
time that imatinib treatment is stopped. 
In this ﬁrst study, we have used numerical results (such as the time required for 
total cancer elimination) to make general observations about the effectiveness of dif­
ferent start times and durations for various treatment interruption programs. In the 
future, we plan to study this optimization problem in more detail; we also plan to 
consider treatment interruption programs in which treatment is stopped more than 
  
once. In (Kim et al. 2008), the authors presented a vaccination strategy as a possible 
immunotherapy treatment for CML, and in a future work, we plan to study combina­
tions of strategic treatment interruptions and vaccinations as a possible treatment for 
CML. 
There are two major drawbacks to the delay differential equations model of Kim et 
al. (2008) that we have used to perform numerical simulations of strategic treatment 
interruption plans. First, the model does not consider competition among hemapoetic 
stem cells. In (Dingli and Michor 2006), Dingli and Michor presented a mathemati­
cal model for cancer stem cell development that assumes that normal stem cells and 
tumor stem cells compete for a common resource. Similarly, in (Roeder and Glauche 
2008), Roeder and Glauche presented a mathematical model which assumes a sto­
chastic competition between normal stem cells and tumor stem cells. Although there 
is not sufﬁcient quantitative data on the growth dynamics of stem cells in patients be­
fore diagnosis to validate one of these models over another, the models that consider 
competition among hemapoetic stem cells are consistent with current clinical data 
(Roeder and Glauche 2008), and in a future work, we plan to numerically simulate 
strategic treatment interruptions using the mathematical models presented in (Dingli 
and Michor 2006) and (Roeder and Glauche 2008). Generally, we hypothesize that 
the inclusion of such a competition process would actually improve the results of 
strategic treatment interruptions. During imatinib treatment of CML, competition be­
tween normal and tumor cells has the effect of increasing the time that CML remains 
in remission. During a treatment interruption, on the other hand, CML is expected to 
relapse, and the leukemia cell population will quickly overpower the normal cell pop­
ulation during a relapse. Thus, the relatively small population of normal cells present 
during a relapse will provide little competition. 
Second, we have not considered here the possibility of imatinib-resistant muta­
tions. In (Komarova and Wodarz 2005), the authors presented a mathematical frame­
work for the emergence of cancers treated with targeted drugs, and for the speciﬁc 
case of CML, the authors estimate that imatinib-resistant stem cells are generated 
maximally at a rate of 10−9–10−8 mutations per division. In future work, we plan to 
study in detail the effects of imatinib-resistant mutations on strategic treatment inter­
ruptions. In particular, we plan to add a set of imatinib-resistant leukemia cells to the 
delay differential equations model of Kim et al. (2008), and to derive new parameter 
values with resistant cells using the patient data presented in (Chen et al. 2008) and 
(Kim et al. 2008). We note that a treatment interruption may potentially impose an 
increased risk of mutations, as drug resistant mutations may be more likely to emerge 
when the patient stops taking imatinib and only low levels remain. For example, in 
(Koup 2004), the author observed that although researchers were initially enthusiastic 
about the possibility of successfully treating HIV with strategic treatment interrup­
tions (primarily to give patients a respite from side effects), several clinical trials 
demonstrated that patients developed an increased amount of drug resistance while 
receiving strategic treatment interruptions. This observation has since been repeated 
in several other studies on the use of treatment interruptions during antiretroviral 
therapy for HIV patients. Thus, the potential effects of treatment interruptions on the 
resistance mutation rate for CML patients should be thoroughly investigated. 
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Appendix A: Exact Solution of the Michor Model 
The system of ODEs that describes the mathematical model of Michor et al. (2005) is  
given below. We include here the second set of differential equations which describe 
the dynamics of the imatinib-resistant leukemia cells. These populations are denoted 
z0, z1, z2, z3 (imatinib-resistant stem cells, progenitor cells, differentiated cells, and 
terminally differentiated cells, respectively). 






= ayy0 − d1y1, 





= azz0 − d1z1, 




= cyy2 − d3y3, dz3 
dt 
= czz2 − d3z3. 
To ﬁnd the exact solution of this system of ODE’s given, we ﬁrst write the system 
in matrix form x� = Ax, where 
� �T 
x = y0 y1 y2 y3 z0 z1 z2 z3 
and A is the coefﬁcient matrix of the system. The eigenvalues of the coefﬁcient matrix 
A are given by 
λ0 = ry(1 − u) − d0, λ4 = rz − d0, 
λ1 = −d1, λ5 = −d1, 
(A.2) 
λ2 = −d2, λ6 = −d2, 
λ3 = −d3, λ7 = −d3, 
and we obtain the following explicit solution of the Michor model for CML: 
(ry(1−u)−d0)ty0(t) = α0e , 
−d1t − ayα0 (ry(1−u)−d0)ty1(t) = α1e e , 
ry(u − 1) + d0 − d1 
  
by(−α1ry + α1ury + α1d0 − α1d1)−d2t + −d1t y2(t) = α2e e 
(−ry(1 − u) + d0 − d1)(d2 − d1) 
α0byay (ry(1−u)−d0)t− e , 
(−ry(1 − u) + d0 − d1)(ry(1 − u) − d0 + d2) 
α0aybycy−d3t −y3(t) = α3e 




−d2t − −d1t+ e e , 
d3 − d2 (d3 − d1)(d1 − d2) 
α0ryu(rz−d0)t − (ry(1−u)−d0)tz0(t) = β0e e , 
ry(u − 1) + rz 
β0az(ry(u − 1) + rz)−d1t + (rz−d0)tz1(t) = β1e e
(ry(u − 1) + rz)(rz − d0 + d1) 
α0uryaz (ry(1−u)−d0)t− e , 
(ry(u − 1) + rz)(ry(1 − u) − d0 + d1)
 
α0ryuazbz
−d2t +z2(t) = β2e 
(ry(1 − u) − d0 + d2)(ry(u − 1) + rz)(ry(u − 1) + d0 − d1) 
(ry(1−u)−d0)t× e
β0azbz (rz−d0)t + β1bz −d1t+ e e , 
(rz − d0 + d2)(rz − d0 + d1) d2 − d1 
β1bzcz β2cz−d3t + −d1t + −d2t z3(t) = β3e e e 
(d2 − d1)(d3 − d1) d3 − d2 
(ry (1−u)−d0)tα0ryuazbzcz · e+ 
(ry(u − 1) + d0 − d1)(ry(1 − u) − d0 + d2)(ry(1 − u) − d0 + d3)(ry(u − 1) + rz) 
β0azbzcz (rz−d0)t+ e , 
(rz − d0 + d1)(rz − d0 + d2)(rz − d0 + d3) 
where the αi and βi are arbitrary constants of integration that are determined by the 
initial conditions of the leukemia cell populations. Since the solutions yi and zi are all 
linear combinations of exponential functions, it is clear that the long-term behavior of 
the system depends only on the relative sizes of the eigenvalues λi, i  = 0..7. For the 
particular values of the parameters given in Table 2, the only positive eigenvalues are 
ry(1 −u) − d0 and rz − d0, so the leukemia stem cell populations y0 and z0 dominate 
the dynamic of this system. 
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